GDC-1971 + atezolizumab

GDC-1971 + atezolizumab is an investigational combination therapy consisting of the small molecule SHP2 inhibitor GDC-1971 (previously RLY-1971) and the monoclonal antibody atezolizumab. GDC-1971 inhibits SHP2, a protein tyrosine phosphatase involved in regulating RAS-driven MAPK signaling, which is implicated in multiple cancers[4][6]. Atezolizumab is a fully humanized IgG1 monoclonal antibody that binds programmed death-ligand 1 (PD-L1) and blocks its interaction with PD-1 and CD80 on immune cells, thereby reversing tumor-induced immunosuppression and enabling T-cell mediated anti-tumor responses[1][5][3]. This combination is under clinical investigation for the treatment of advanced or metastatic solid tumors, with a specific focus on non-small cell lung cancer, head and neck squamous cell carcinoma, and BRAF wild-type melanoma[2].